Testing two drugs for Crohn's with weight issues
Treatments studied
Part of Digestive system, Hormones & metabolism clinical trials.
This trial tests two study drugs, mirikizumab and tirzepatide, in people with moderate to severe Crohn's disease who also have overweight or obesity. The goal is to see if these treatments can help control Crohn's symptoms and inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Crohn's disease or Crohn's with fistulas around the anus.
- Your body mass index (BMI) is 30 or higher, or at least 27 with a weight-related condition like high blood pressure, type 2 diabetes, high cholesterol, sleep apnea, or heart disease.
- Your Crohn's is moderately to severely active, meaning you have symptoms like abdominal pain or diarrhea and inflammation seen on a colonoscopy.
- You have already tried at least one standard Crohn's treatment that didn't work well enough or caused side effects.
- You do not have a current infection, abscess, stoma, or a history of more than 3 small bowel surgeries.
- You have not had significant weight change (more than 5% of your body weight) in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding mirikizumab to the weight-loss drug tirzepatide helps people with moderate-to-severe ulcerative colitis who also have obesity or overweight. It aims to see if the combination reduces bowel inflammation and helps with weight management.
This trial tests new targeted therapies for adults with moderate to severe Crohn's disease that hasn't improved with standard treatments. The goal is to see if these drugs can reduce inflammation and improve symptoms.
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
This study tests mirikizumab to reduce inflammation and symptoms in children with Crohn’s disease that is currently active. It may help if your Crohn’s has not improved enough (or stopped working) with at least one other Crohn’s medicine.
This study tests a medication called mirikizumab (an injection) in people over 60 with moderate to severe Crohn's disease or ulcerative colitis. The goal is to see if it effectively reduces inflammation and helps symptoms, while also checking how safe it is for older adults.
This trial is testing a new investigational treatment called TRX103 for adults with moderate to severe Crohn's disease that has not responded to at least two other advanced therapies. The study aims to see if this treatment can reduce inflammation and improve symptoms.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.